{"id":"NCT02446899","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus","officialTitle":"A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-09","primaryCompletion":"2018-09-27","completion":"2018-09-27","firstPosted":"2015-05-18","resultsPosted":"2020-03-18","lastUpdate":"2023-01-10"},"enrollment":373,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Active Systemic Lupus Erythematosus"],"interventions":[{"type":"BIOLOGICAL","name":"Anifrolumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Anifrolumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).","primaryOutcome":{"measure":"Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52","timeFrame":"Baseline; Week 52","effectByArm":[{"arm":"Anifrolumab 300 mg","deltaMin":86,"sd":null},{"arm":"Placebo","deltaMin":57,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0013"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":113,"countries":["United States","Argentina","Belgium","Brazil","Bulgaria","Canada","France","Germany","Japan","Lithuania","Mexico","Russia","South Africa","South Korea","Spain"]},"refs":{"pmids":["36690388","36018235","35580976","35338035","35157371","34528084","33977796","33913260","33687069","31851795"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D3461C00004&attachmentIdentifier=3a779c1e-b522-4240-8d7f-fd4e6848a9d1&fileName=D3461C00004_CSP_redactions_applied.pdf&","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3461C00004&amp;attachmentIdentifier=c6a17786-1293-46c9-87e6-d6dda2c86d2a&amp;fileName=D3461C00004_Redacted_SAP.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":180},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Urinary tract infection","Infusion related reaction","Bronchitis"]}}